Value Sense
HALO
Halozyme Therapeutics, Inc. (HALO)
Last Price$65.21.3%
Market Cap$8,236.6M
Intrinsic value score
8/10
Great
Intrinsic value
$56.1
DCF value - $65.0 Relative value - $47.2
Overvalued
13.8%
LTM P/E
18.5x
Peer set median 5.6x
Discount rate
8.8%
HALO
is 13.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

HALO Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 21, 2025 HALO Relative Value is $47.0, which is overvalued by 27.9%, compared to current share price of $65.2.
DCF Value vs Current Share Price
As of Mar 21, 2025 HALO DCF Value is $65.4, which is undervalued by 0.3%, compared to current share price of $65.2.
Methodology
Price per share, $
HALO
Intrinsic value$56.1
Overvalued by13.8%
Current share price
65.2
Relative value
47.0
DCF value
65.4

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance 5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

HALO Historical Intrinsic Value

Crunching data... Almost there!

HALO vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Halozyme Therapeutics, Inc. logo
Halozyme Therapeutics, Inc.HALO
(13.8%)
22.4%
64.3%
43.7%
Median Peer Set
14.8%
N/A
(2.4%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(97.1%)
N/A
(68.7%)
N/A
argenx SE logo
argenx SEARGX
(77.6%)
198.6%
(60.5%)
(24.1%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
(71.4%)
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(69.6%)
23.0%
(38.6%)
(12.4%)
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
(31.3%)
18.0%
139.3%
15.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
53.1%
8.3%
10.4%
31.1%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
66.0%
23.6%
25.7%
41.5%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
87.6%
(3.8%)
(43.7%)
37.9%
BioNTech SE logo
BioNTech SEBNTX
246.7%
(27.9%)
N/A
(24.2%)
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
1,182.4%
73.7%
467.1%
(35.9%)

Explore more intrinsic value tools hub for HALO

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Halozyme Therapeutics, Inc. intrinsic value?

As of Mar 21, 2025, Halozyme Therapeutics, Inc. Intrinsic Value is $56.1. This suggests it may be overvalued by 13.8% compared to its current price of around $65.2.

What is Halozyme Therapeutics, Inc. DCF (discounted cash flow) valuation?

As of Mar 21, 2025, Halozyme Therapeutics, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $65.4. This suggests it may be overvalued by 0.3% to its current price of around $65.2, using a discount rate of 8.8% and terminal growth rate of 3.0%.

Is Halozyme Therapeutics, Inc. overvalued or undervalued?

Halozyme Therapeutics, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $56.1, compared to a market price of around $65.2. This suggests a potential overvaluation of 13.8%.